Condition (MeSH)
Mania
ClinicalTrials.gov lists 158 trials for Mania or a narrower condition beneath it. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. has the most among industry and government lead sponsors, with 13.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
158 of the 158 trials are tagged with Mania itself; the rest are tagged with a narrower condition beneath it.
When did Mania trials start? (31)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 15
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 11 |
| 2024 | 6 |
| 2023 | 4 |
| 2022 | 4 |
| 2021 | 2 |
| 2020 | 1 |
| 2018 | 2 |
| 2017 | 4 |
| 2015 | 1 |
| 2014 | 1 |
Showing 10 of 31 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 2 trials starting in 2026 and about 6 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 34 months from start to primary completion across 8 trials still running at the 2026-10-09 snapshot; registered median of 30 months across 101 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Mania trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 1 |
| Phase 2 | 22 |
| Phase 2/3 | 1 |
| Phase 3 | 51 |
| Phase 4 | 34 |
| Not applicable | 23 |
| Observational | 23 |
How many Mania trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 11 |
| Active, not recruiting | 1 |
| Completed | 122 |
| Suspended | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Mania trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 13 |
| National Institute of Mental Health (NIMH) | 8 |
| AstraZeneca | 7 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 |
| Forest Laboratories | 5 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Mania? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| LI | 10 |
| Sodium Valproate | 5 |
| Aripiprazole | 5 |
| Cariprazine | 5 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| IR (Immediate-Release) quetiapine fumarate (drug) | 13 |
| IR Risperidone | 9 |
| IM olanzapine | 6 |
| Topiramate IR | 5 |
| SODIUM DIVALPROATE | 5 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Mania trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Mania | 99 | 13 |
| Depression | 31 | 6 |
| Psychiatric rehospitalization | 25 | 1 |
| Bipolar disorder | 24 | 6 |
| Suicidal ideation | 24 | 7 |
Showing 5 of 10 adverse events.
Which publications cover Mania? (35)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The Ottawa sunglasses at night study: A randomized controlled trial of blue-blocking glasses for mania. | Journal of affective disorders | 2026 | Yes |
| Bipolar disorder at mixed states and major depressive disorder with mixed features differ in peripheral biochemical parameters. | BMC psychiatry | 2025 | Yes |
| A novel murine model of mania. | Molecular psychiatry | 2023 | Yes |
| Findings from a pilot open-label trial of N-acetylcysteine for the treatment of pediatric mania and hypomania. | BMC psychiatry | 2022 | Yes |
| Irregular eating patterns associate with hypomanic symptoms in bipolar disorders. | Nutritional neuroscience | 2021 | Yes |
Showing 5 of 35 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.